<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144595">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01885585</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-222</org_study_id>
    <nct_id>NCT01885585</nct_id>
  </id_info>
  <brief_title>Eliquis Regulatory Post Marketing Surveillance (rPMS)</brief_title>
  <official_title>Eliquis (Apixaban) Regulatory Post Marketing Surveillance in Clinical Practice for Venous Thromboembolism (VTE) Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the
      clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the
      safety and effectiveness information about Eliquis in general practice
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs) and serious AEs</measure>
    <time_frame>Up to 30 days after last study drug dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Patients with risk of VTE</arm_group_label>
    <description>Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <arm_group_label>Patients with risk of VTE</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic Patients must be ≥19 years of age, at risk for venous thrombosis, and
        have elected to undergo total hip replacement arthroplasty or total knee replacement
        arthroplasty will be included in this study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed data release

          -  Patients undergoing elective total hip replacement arthroplasty or elective total
             knee replacement arthroplasty

        Exclusion Criteria:

          -  Being treated for an indication not approved for the use of Eliquis® in Korea

          -  Is contraindicated for the use of Eliquis® as described in the Korean label
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 1, 2013</lastchanged_date>
  <firstreceived_date>June 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
